Renaud Ronald C JR

SEC source: 0001193125-26-268168 · ownership.xml · derivative · entry 1

Renaud Ronald C JR · CIK 0001354434 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,096

Underlying: Common Stock · 17,096 shares

Expires 2036-06-08

F1 · derivative.exercise_date: The shares underlying this option shall vest in full upon the earlier of (i) June 9, 2027 and (ii) the date of the next Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continued service on such vesting date.

SEC source: 0001193125-26-267493 · ownership.xml · derivative · entry 2

Renaud Ronald C JR · CIK 0001354434 · Director · CEO & President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 817,826

Underlying: Common Stock · 38,094 shares

Expires 2034-09-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The options vested and became exercisable as to 33% of the total shares on September 9, 2025 and thereafter in 24 substantially equal monthly installments, subject to the Reporting Person's continued service on each such vesting date.

SEC source: 0001193125-26-267493 · ownership.xml · nonDerivative · entry 1

Renaud Ronald C JR · CIK 0001354434 · Director · CEO & President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 38,094

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001193125-26-164299 · ownership.xml · derivative · entry 2

Renaud Ronald C JR · CIK 0001354434 · Director · CEO & President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 300,000

Underlying: Common Stock · 300,000 shares

Expires 2036-04-16

F2 · derivative.exercise_date: The options vest and become exercisable, if at all, as to all of the underlying shares if (i) the average daily closing price of the Company's common stock on Nasdaq during any 30 consecutive calendar-day period during the period beginning October 16, 2026 and ending on April 16, 2030 (the "Performance Measurement Period"), or (ii) the stock price in a change in control transaction that occurs during the Performance Measurement Period, equals or exceeds $40 per share, in each case subject to the Reporting Person's continued service through such vesting date.

SEC source: 0001193125-26-164299 · ownership.xml · derivative · entry 1

Renaud Ronald C JR · CIK 0001354434 · Director · CEO & President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 300,000

Underlying: Common Stock · 300,000 shares

Expires 2036-04-16

F1 · derivative.exercise_date: The options vest and become exercisable as to 25% of the underlying shares on April 16, 2027 and thereafter in 36 substantially equal monthly installments, subject to the Reporting Person's continued service through each such vesting date.

SEC source: 0000950170-25-085373 · ownership.xml · derivative · entry 1

Renaud Ronald C JR · CIK 0001354434 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,096

Underlying: Common Stock · 17,096 shares

Expires 2035-06-09

F1 · derivative.exercise_date: The shares underlying this option shall vest upon the earlier of (i) June 10, 2026 and (ii) the date of the next Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continued service on such vesting date.

SEC source: 0000950170-24-114687 · ownership.xml · derivative · entry 1

Renaud Ronald C JR · CIK 0001354434 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,096

Underlying: Common Stock · 17,096 shares

Expires 2034-10-09

F1 · derivative.exercise_date: The shares underlying this option shall vest upon the earlier of (i) October 10, 2025 and (ii) the date of the next Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continued service on such vesting date.

SEC source: 0000950170-24-090851 · ownership.xml · derivative · entry 5

Renaud Ronald C JR · CIK 0001354434 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 320,742 shares

Expires not disclosed

F5 · derivative.exercise_price: At the Effective Time, each outstanding award of performance-based restricted stock units ("PSUs") was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the aggregate number of shares subject to such PSUs, determined assuming that the applicable performance goals had been deemed to be achieved at the greater of target and actual level of performance, multiplied by (ii) the Merger Consideration, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement.

F5 · derivative.exercise_date: At the Effective Time, each outstanding award of performance-based restricted stock units ("PSUs") was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the aggregate number of shares subject to such PSUs, determined assuming that the applicable performance goals had been deemed to be achieved at the greater of target and actual level of performance, multiplied by (ii) the Merger Consideration, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement.

F5 · derivative.expiration_date: At the Effective Time, each outstanding award of performance-based restricted stock units ("PSUs") was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the aggregate number of shares subject to such PSUs, determined assuming that the applicable performance goals had been deemed to be achieved at the greater of target and actual level of performance, multiplied by (ii) the Merger Consideration, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement.

SEC source: 0000950170-24-090851 · ownership.xml · derivative · entry 4

Renaud Ronald C JR · CIK 0001354434 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 284,023 shares

Expires not disclosed

F4 · derivative.exercise_price: At the Effective Time, (a) 50% of each outstanding award of restricted stock units ("RSUs") that was granted on or after December 6, 2023 was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the aggregate number of shares underlying such RSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement, and (b) the remaining 50% was assumed by Parent and converted into RSUs with respect to shares of the Parent's common stock in accordance with the terms of the Merger Agreement.

F4 · derivative.exercise_date: At the Effective Time, (a) 50% of each outstanding award of restricted stock units ("RSUs") that was granted on or after December 6, 2023 was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the aggregate number of shares underlying such RSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement, and (b) the remaining 50% was assumed by Parent and converted into RSUs with respect to shares of the Parent's common stock in accordance with the terms of the Merger Agreement.

F4 · derivative.expiration_date: At the Effective Time, (a) 50% of each outstanding award of restricted stock units ("RSUs") that was granted on or after December 6, 2023 was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the aggregate number of shares underlying such RSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement, and (b) the remaining 50% was assumed by Parent and converted into RSUs with respect to shares of the Parent's common stock in accordance with the terms of the Merger Agreement.

SEC source: 0000950170-24-090851 · ownership.xml · derivative · entry 3

Renaud Ronald C JR · CIK 0001354434 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 215,749 shares

Expires not disclosed

F3 · derivative.exercise_price: At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of common stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement.

F3 · price: At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of common stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement.

F3 · derivative.exercise_date: At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of common stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement.

F3 · derivative.expiration_date: At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of common stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement.

SEC source: 0000950170-24-090851 · ownership.xml · nonDerivative · entry 2

Renaud Ronald C JR · CIK 0001354434 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Indirect · By Trust

Disclosed balance after: 0

F1 · price: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated December 6, 2023, by and among AbbVie Inc. ("Parent"), Symphony Harlan LLC, Symphony Harlan Merger Sub Inc. ("Merger Sub") and Cerevel Therapeutics Holdings, Inc. ("Issuer"), on August 1, 2024 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock was cancelled and converted into the right to receive $45.00 in cash (the "Merger Consideration"), without interest.

F2 · ownership.nature: Shares held by The Ronald C Renaud Jr Trust 2 U/A DTD 06/08/2007, of which the Reporting Person and his spouse serve as trustees. The Reporting Person disclaims Section 16 beneficial ownership of such shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that he has beneficial ownership of such shares for Section 16 or any other purpose.

SEC source: 0000950170-24-090851 · ownership.xml · nonDerivative · entry 1

Renaud Ronald C JR · CIK 0001354434 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F1 · price: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated December 6, 2023, by and among AbbVie Inc. ("Parent"), Symphony Harlan LLC, Symphony Harlan Merger Sub Inc. ("Merger Sub") and Cerevel Therapeutics Holdings, Inc. ("Issuer"), on August 1, 2024 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock was cancelled and converted into the right to receive $45.00 in cash (the "Merger Consideration"), without interest.

SEC source: 0000950170-24-006667 · ownership.xml · derivative · entry 1

Renaud Ronald C JR · CIK 0001354434 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 284,023

Underlying: Common Stock · 284,023 shares

Expires not disclosed

F1 · derivative.exercise_price: The shares reported in this transaction represent Restricted Stock Units ("RSUs") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan (the "Plan"). Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs vest in four equal annual installments on each of January 19, 2025, January 19, 2026, January 19, 2027 and January 19, 2028, subject to the Reporting Person's continued service on each such vesting date.

F1 · derivative.exercise_date: The shares reported in this transaction represent Restricted Stock Units ("RSUs") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan (the "Plan"). Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs vest in four equal annual installments on each of January 19, 2025, January 19, 2026, January 19, 2027 and January 19, 2028, subject to the Reporting Person's continued service on each such vesting date.

F1 · derivative.expiration_date: The shares reported in this transaction represent Restricted Stock Units ("RSUs") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan (the "Plan"). Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs vest in four equal annual installments on each of January 19, 2025, January 19, 2026, January 19, 2027 and January 19, 2028, subject to the Reporting Person's continued service on each such vesting date.

SEC source: 0000950170-23-072374 · ownership.xml · derivative · entry 3

Renaud Ronald C JR · CIK 0001354434 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 160,452 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each RSU represented the contingent right to receive one share of the Issuer's common stock.

F1 · kind: In order to mitigate the impact of Sections 280G and 4999 of the Internal Revenue Code of 1986, as amended, in connection with the transactions contemplated by the Agreement and Plan of Merger, dated as of December 6, 2023, by and among Cerevel Therapeutics Holdings, Inc. (the "Issuer"), AbbVie Inc., Symphony Harlan LLC and Symphony Harlan Merger Sub Inc., the restricted stock units ("RSUs") held by the Reporting Person vested in full on December 19, 2023, subject to certain repayment conditions in the event that the Reporting Person's employment terminates for any reason prior to the date the RSUs otherwise would vest.

F1 · derivative.exercise_date: In order to mitigate the impact of Sections 280G and 4999 of the Internal Revenue Code of 1986, as amended, in connection with the transactions contemplated by the Agreement and Plan of Merger, dated as of December 6, 2023, by and among Cerevel Therapeutics Holdings, Inc. (the "Issuer"), AbbVie Inc., Symphony Harlan LLC and Symphony Harlan Merger Sub Inc., the restricted stock units ("RSUs") held by the Reporting Person vested in full on December 19, 2023, subject to certain repayment conditions in the event that the Reporting Person's employment terminates for any reason prior to the date the RSUs otherwise would vest.

F1 · derivative.expiration_date: In order to mitigate the impact of Sections 280G and 4999 of the Internal Revenue Code of 1986, as amended, in connection with the transactions contemplated by the Agreement and Plan of Merger, dated as of December 6, 2023, by and among Cerevel Therapeutics Holdings, Inc. (the "Issuer"), AbbVie Inc., Symphony Harlan LLC and Symphony Harlan Merger Sub Inc., the restricted stock units ("RSUs") held by the Reporting Person vested in full on December 19, 2023, subject to certain repayment conditions in the event that the Reporting Person's employment terminates for any reason prior to the date the RSUs otherwise would vest.

SEC source: 0000950170-23-072374 · ownership.xml · nonDerivative · entry 1

Renaud Ronald C JR · CIK 0001354434 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 160,452

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: In order to mitigate the impact of Sections 280G and 4999 of the Internal Revenue Code of 1986, as amended, in connection with the transactions contemplated by the Agreement and Plan of Merger, dated as of December 6, 2023, by and among Cerevel Therapeutics Holdings, Inc. (the "Issuer"), AbbVie Inc., Symphony Harlan LLC and Symphony Harlan Merger Sub Inc., the restricted stock units ("RSUs") held by the Reporting Person vested in full on December 19, 2023, subject to certain repayment conditions in the event that the Reporting Person's employment terminates for any reason prior to the date the RSUs otherwise would vest.

F2 · price: Each RSU represented the contingent right to receive one share of the Issuer's common stock.

SEC source: 0000950170-23-039169 · ownership.xml · nonDerivative · entry 1

Renaud Ronald C JR · CIK 0001354434 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Indirect · By Trust

Disclosed balance after: 83,857

F1 · price: The price reported in column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $23.78 - $24.01. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

F2 · ownership.nature: Shares held by The Ronald C Renaud Jr Trust 2 U/A DTD 06/08/2007, of which the Reporting Person and his spouse serve as trustees. The Reporting Person disclaims Section 16 beneficial ownership of such shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that he has beneficial ownership of such shares for Section 16 or any other purpose.

SEC source: 0000899243-23-015539 · doc4.xml · derivative · entry 3

Renaud Ronald C JR · CIK 0001354434 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 160,371

Underlying: Common Stock · 160,371 shares

Expires not disclosed

F3 · derivative.exercise_price: The shares reported in this transaction represent the target number of performance-based RSUs ("PSUs") granted under the Plan. The PSUs shall vest at the end of a four-year performance period following the Grant Date based on absolute total stockholder return ("TSR") performance measured at the end of the performance period (with a payout range of 0% to 250% of the target number of PSUs, or 50% to 275% of the target number of PSUs upon a Sale Event (as defined in an Employment Agreement between the Issuer and the Reporting Person)), subject to the Reporting Person's continued service at such time. Excludes an additional 160,371 target PSUs issued on the same Grant Date that are subject to vesting based on certain relative TSR performance metrics.

F3 · derivative.exercise_date: The shares reported in this transaction represent the target number of performance-based RSUs ("PSUs") granted under the Plan. The PSUs shall vest at the end of a four-year performance period following the Grant Date based on absolute total stockholder return ("TSR") performance measured at the end of the performance period (with a payout range of 0% to 250% of the target number of PSUs, or 50% to 275% of the target number of PSUs upon a Sale Event (as defined in an Employment Agreement between the Issuer and the Reporting Person)), subject to the Reporting Person's continued service at such time. Excludes an additional 160,371 target PSUs issued on the same Grant Date that are subject to vesting based on certain relative TSR performance metrics.

F3 · derivative.expiration_date: The shares reported in this transaction represent the target number of performance-based RSUs ("PSUs") granted under the Plan. The PSUs shall vest at the end of a four-year performance period following the Grant Date based on absolute total stockholder return ("TSR") performance measured at the end of the performance period (with a payout range of 0% to 250% of the target number of PSUs, or 50% to 275% of the target number of PSUs upon a Sale Event (as defined in an Employment Agreement between the Issuer and the Reporting Person)), subject to the Reporting Person's continued service at such time. Excludes an additional 160,371 target PSUs issued on the same Grant Date that are subject to vesting based on certain relative TSR performance metrics.

SEC source: 0000899243-23-015539 · doc4.xml · derivative · entry 2

Renaud Ronald C JR · CIK 0001354434 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 160,452

Underlying: Common Stock · 160,452 shares

Expires not disclosed

F2 · derivative.exercise_price: The shares reported in this transaction represent Restricted Stock Units ("RSUs") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan (the "Plan"). Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs vest in four equal annual installments on each of June 12, 2024, June 12, 2025, June 12, 2026 and June 12, 2027, subject to the Reporting Person's continued service on each such vesting date.

F2 · derivative.exercise_date: The shares reported in this transaction represent Restricted Stock Units ("RSUs") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan (the "Plan"). Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs vest in four equal annual installments on each of June 12, 2024, June 12, 2025, June 12, 2026 and June 12, 2027, subject to the Reporting Person's continued service on each such vesting date.

F2 · derivative.expiration_date: The shares reported in this transaction represent Restricted Stock Units ("RSUs") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan (the "Plan"). Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs vest in four equal annual installments on each of June 12, 2024, June 12, 2025, June 12, 2026 and June 12, 2027, subject to the Reporting Person's continued service on each such vesting date.

SEC source: 0000899243-23-015539 · doc4.xml · derivative · entry 1

Renaud Ronald C JR · CIK 0001354434 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 215,749

Underlying: Common Stock · 215,749 shares

Expires 2033-06-12

F1 · derivative.exercise_date: 25% of this option shall vest and become exercisable on June 12, 2024, with the remainder vesting in thirty-six (36) monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

SEC source: 0001140361-22-024159 · form4.xml · derivative · entry 2

Renaud Ronald C JR · CIK 0001354434 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,500

Underlying: Common Stock · 31,500 shares

Expires 2032-06-22

F2 · derivative.exercise_date: The option shall vest on the earlier of June 23, 2023 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service.

SEC source: 0001140361-22-024159 · form4.xml · nonDerivative · entry 1

Renaud Ronald C JR · CIK 0001354434 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,500

F1 · shares: These restricted stock units shall vest on the earlier of June 23, 2023 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service.

SEC source: 0000899243-22-022239 · doc4.xml · derivative · entry 1

Renaud Ronald C JR · CIK 0001354434 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,419

Underlying: Common Stock · 13,419 shares

Expires 2032-06-09

F1 · derivative.exercise_date: This option shall vest in full upon the earlier of (i) June 9, 2023 or (ii) the date of the next annual meeting, all vesting shall cease if the director resigns from the Board or otherwise ceases to service as a director.

SEC source: 0000899243-21-049685 · doc4.xml · derivative · entry 1

Renaud Ronald C JR · CIK 0001354434 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,419

Underlying: Common Stock · 13,419 shares

Expires 2031-12-21

F1 · derivative.exercise_date: This option shall vest (1) 25% on December 21, 2022, and the remaining shall vest in equal monthly installments over the next 36 months.

SEC source: 0001209191-21-056062 · doc4.xml · derivative · entry 8

Renaud Ronald C JR · CIK 0001354434 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 89,996 shares

Expires 2028-03-06

F2 · kind: Under the terms of the Tender Offer, Issuer outstanding stock options, if not vested became vested, and all Issuer stock options were converted into cash consideration at the amount of the difference between the exercise price of the option and the Tender Offer price of $38.00 per share.

F7 · derivative.exercise_date: This option was granted on March 7, 2018. The shares underlying the option are scheduled to vest over four years, with 25% of the shares vesting on March 7, 2019 and the remainder vesting in equal monthly installment through March 7, 2022.

SEC source: 0001209191-21-056062 · doc4.xml · derivative · entry 7

Renaud Ronald C JR · CIK 0001354434 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,071,009 shares

Expires 2027-12-21

F2 · kind: Under the terms of the Tender Offer, Issuer outstanding stock options, if not vested became vested, and all Issuer stock options were converted into cash consideration at the amount of the difference between the exercise price of the option and the Tender Offer price of $38.00 per share.

F6 · derivative.exercise_date: This option was granted on December 22, 2017. The shares underlying became fully vested on March 9, 2021.

SEC source: 0001209191-21-056062 · doc4.xml · derivative · entry 6

Renaud Ronald C JR · CIK 0001354434 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 325,000 shares

Expires 2031-03-09

F2 · kind: Under the terms of the Tender Offer, Issuer outstanding stock options, if not vested became vested, and all Issuer stock options were converted into cash consideration at the amount of the difference between the exercise price of the option and the Tender Offer price of $38.00 per share.

F5 · derivative.exercise_date: This option was granted on March 9, 2021. This option will vest as to 25% of the shares on March 9, 2022, and in thirty-six equal monthly installments thereafter as to the remaining shares through March 9, 2025.

SEC source: 0001209191-21-056062 · doc4.xml · derivative · entry 5

Renaud Ronald C JR · CIK 0001354434 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 525,000 shares

Expires 2030-03-02

F2 · kind: Under the terms of the Tender Offer, Issuer outstanding stock options, if not vested became vested, and all Issuer stock options were converted into cash consideration at the amount of the difference between the exercise price of the option and the Tender Offer price of $38.00 per share.

F4 · derivative.exercise_date: This option was granted on March 3, 2020. This option will vest as to 25% of the shares on March 3, 2021, and in thirty-six equal monthly installments thereafter as to the remaining shares through March 3, 2024.

SEC source: 0001209191-21-056062 · doc4.xml · derivative · entry 4

Renaud Ronald C JR · CIK 0001354434 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 500,000 shares

Expires 2029-03-07

F2 · kind: Under the terms of the Tender Offer, Issuer outstanding stock options, if not vested became vested, and all Issuer stock options were converted into cash consideration at the amount of the difference between the exercise price of the option and the Tender Offer price of $38.00 per share.

F3 · derivative.exercise_date: This option was granted on March 8, 2019. This option will vest as to 25% of the shares on March 8, 2020, and in thirty-six equal monthly installments thereafter as to the remaining shares through March 8, 2023.

SEC source: 0001209191-21-056062 · doc4.xml · nonDerivative · entry 3

Renaud Ronald C JR · CIK 0001354434 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · By Ronald C. Renaud, Jr. Trust - 2007

Disclosed balance after: 0

F1 · date: As of September 14, 2021, Issuer was acquired in a cash tender by an indirect subsidiary of Sanofi, a French societe anonyme at a purchase price of $38.00 per share (the "Tender Offer"), as described more fully in the Schedule 14D-9 filed by the Issuer on August 16, 2021.

F1 · kind: As of September 14, 2021, Issuer was acquired in a cash tender by an indirect subsidiary of Sanofi, a French societe anonyme at a purchase price of $38.00 per share (the "Tender Offer"), as described more fully in the Schedule 14D-9 filed by the Issuer on August 16, 2021.

SEC source: 0001209191-21-056062 · doc4.xml · nonDerivative · entry 2

Renaud Ronald C JR · CIK 0001354434 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · By Ronald Renaud 2014 Irrevocable Family Trust

Disclosed balance after: 0

F1 · date: As of September 14, 2021, Issuer was acquired in a cash tender by an indirect subsidiary of Sanofi, a French societe anonyme at a purchase price of $38.00 per share (the "Tender Offer"), as described more fully in the Schedule 14D-9 filed by the Issuer on August 16, 2021.

F1 · kind: As of September 14, 2021, Issuer was acquired in a cash tender by an indirect subsidiary of Sanofi, a French societe anonyme at a purchase price of $38.00 per share (the "Tender Offer"), as described more fully in the Schedule 14D-9 filed by the Issuer on August 16, 2021.

SEC source: 0001209191-21-056062 · doc4.xml · nonDerivative · entry 1

Renaud Ronald C JR · CIK 0001354434 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · date: As of September 14, 2021, Issuer was acquired in a cash tender by an indirect subsidiary of Sanofi, a French societe anonyme at a purchase price of $38.00 per share (the "Tender Offer"), as described more fully in the Schedule 14D-9 filed by the Issuer on August 16, 2021.

F1 · kind: As of September 14, 2021, Issuer was acquired in a cash tender by an indirect subsidiary of Sanofi, a French societe anonyme at a purchase price of $38.00 per share (the "Tender Offer"), as described more fully in the Schedule 14D-9 filed by the Issuer on August 16, 2021.

SEC source: 0001140361-21-020441 · form4.xml · derivative · entry 2

Renaud Ronald C JR · CIK 0001354434 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,500

Underlying: Common Stock · 17,500 shares

Expires 2031-06-07

F2 · derivative.exercise_date: The option shall vest on the earlier of June 8, 2022 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service.

SEC source: 0001140361-21-020441 · form4.xml · nonDerivative · entry 1

Renaud Ronald C JR · CIK 0001354434 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,000

F1 · shares: These restricted stock units shall vest on the earlier of June 8, 2022 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service.

SEC source: 0001209191-21-026217 · doc4.xml · derivative · entry 4

Renaud Ronald C JR · CIK 0001354434 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,071,009

Underlying: Common Stock · 9,026 shares

Expires 2027-12-21

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: This option was granted on December 22, 2017. The shares underlying the option vested over four years in equal monthly installments through March 9, 2021.

SEC source: 0001209191-21-026217 · doc4.xml · nonDerivative · entry 1

Renaud Ronald C JR · CIK 0001354434 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 503,321

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-21-056060 · doc4a.xml · derivative · entry 4

Renaud Ronald C JR · CIK 0001354434 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,071,009

Underlying: Common Stock · 9,026 shares

Expires 2027-12-21

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: This option was granted on December 22, 2017. The shares underlying the option vested over four years in equal monthly installments through March 9, 2021.

SEC source: 0001209191-21-056060 · doc4a.xml · nonDerivative · entry 1

Renaud Ronald C JR · CIK 0001354434 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 503,231

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: The original Form 4 filed on April 9, 2021 inadvertently reported the incorrect number of securities beneficially owned following the reported transaction by an additional 90 shares. The original Form 4 filed on April 9, 2021 stated that 503,321 shares were owned after the transaction. The correct number of shares is 503,231. This amendment is being filed solely to correct the number of securities beneficially owned.

SEC source: 0001209191-21-019305 · doc4.xml · derivative · entry 1

Renaud Ronald C JR · CIK 0001354434 · Director · Chief Executive Officer, Pres.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 325,000

Underlying: Common Stock · 325,000 shares

Expires 2031-03-09

F1 · derivative.exercise_date: This option will vest as to 25% of the shares on March 9, 2022, and in thirty-six equal monthly installments thereafter as to the remaining shares though March 9, 2025.

SEC source: 0001209191-21-003697 · doc4.xml · derivative · entry 6

Renaud Ronald C JR · CIK 0001354434 · Director · Chief Executive Officer, Pres.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 89,996

Underlying: Common Stock · 1 shares

Expires 2028-03-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: This option was granted on March 7, 2018. The shares underlying the option are scheduled to vest over four years, with 25% of the shares vesting on March 7, 2019 and the remainder vesting in equal monthly installment through March 7, 2022.

SEC source: 0001209191-21-003697 · doc4.xml · derivative · entry 5

Renaud Ronald C JR · CIK 0001354434 · Director · Chief Executive Officer, Pres.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,080,035

Underlying: Common Stock · 5,638 shares

Expires 2027-12-21

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: This option was granted on December 22, 2017. The shares underlying the option are scheduled to vest over four years in equal monthly installments through March 9, 2021.

SEC source: 0001209191-21-003697 · doc4.xml · nonDerivative · entry 2

Renaud Ronald C JR · CIK 0001354434 · Director · Chief Executive Officer, Pres.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 494,205

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-21-003697 · doc4.xml · nonDerivative · entry 1

Renaud Ronald C JR · CIK 0001354434 · Director · Chief Executive Officer, Pres.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 494,204

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-20-059255 · doc4.xml · derivative · entry 6

Renaud Ronald C JR · CIK 0001354434 · Director · Chief Executive Officer, Pres.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 89,997

Underlying: Common Stock · 3 shares

Expires 2028-03-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: This option was granted on March 7, 2018. 25% of the shares vested on March 7, 2019 and the remainder are scheduled to vest in equal monthly installment through March 7, 2022.

SEC source: 0001209191-20-059255 · doc4.xml · derivative · entry 5

Renaud Ronald C JR · CIK 0001354434 · Director · Chief Executive Officer, Pres.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,085,673

Underlying: Common Stock · 53,004 shares

Expires 2027-12-21

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: This option was granted on December 22, 2017. The shares underlying the option are scheduled to vest over four years in equal monthly installments through March 9, 2021.

SEC source: 0001209191-20-059255 · doc4.xml · nonDerivative · entry 2

Renaud Ronald C JR · CIK 0001354434 · Director · Chief Executive Officer, Pres.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 488,566

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-20-059255 · doc4.xml · nonDerivative · entry 1

Renaud Ronald C JR · CIK 0001354434 · Director · Chief Executive Officer, Pres.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 488,563

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-20-026420 · doc4.xml · derivative · entry 1

Renaud Ronald C JR · CIK 0001354434 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 71,500

Underlying: Common Stock · 71,500 shares

Expires 2030-04-28

F1 · derivative.exercise_date: 1/3rd of the shares will vest on the first, second and third anniversaries of the grant date, subject to the Director's Continuous Service (as defined in the Plan).

SEC source: 0001209191-20-016801 · doc4.xml · derivative · entry 1

Renaud Ronald C JR · CIK 0001354434 · Director · Chief Executive Officer · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 525,000

Underlying: Common Stock · 525,000 shares

Expires 2030-03-02

F1 · derivative.exercise_date: This option will vest as to 25% of the shares on March 3, 2021, and in thirty-six equal monthly installments thereafter as to the remaining shares through March 3, 2024.

SEC source: 0001209191-19-038719 · doc4.xml · derivative · entry 1

Renaud Ronald C JR · CIK 0001354434 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,000

Underlying: Common Stock · 21,000 shares

Expires 2029-06-19

F1 · derivative.exercise_date: The shares subject to the option vest in a series of 12 equal monthly installments from the date of grant; provided, however, that the option shall become fully vested on the date that is the earlier of (i) the one-year anniversary of the date of grant and (ii) the date of the Company's 2020 annual stockholder meeting.

SEC source: 0001209191-19-018962 · doc4.xml · derivative · entry 1

Renaud Ronald C JR · CIK 0001354434 · Director · Chief Executive Officer · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 500,000

Underlying: Common Stock · 500,000 shares

Expires 2029-03-07

F1 · derivative.exercise_date: This option will vest as to 25% of the shares on March 8, 2020, and in thirty-six equal monthly installments thereafter as to the remaining shares through March 8, 2023.